NASDAQ$MDXG

Mimedx Group Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Reported net sales of $81.3 million, net income of $1.2 million, and Adjusted EBITDA of $14.1 million.

MiMedx Group, Inc. announced strong second quarter 2023 results, with net sales of $81.3 million and a net income of $1.2 million. The company's top-line growth was 21.5% compared to the prior year. They are increasing full-year 2023 net sales growth guidance to the mid to high teens.

  • Net sales increased by 21.5% over second quarter 2022.
  • GAAP net income was $1.2 million, compared to a net loss of $10.9 million for the prior year period.
  • Adjusted EBITDA was $14.1 million, compared to an Adjusted EBITDA loss of $1.0 million for the prior year period.
  • Increased full-year 2023 net sales percentage growth rate to be in the mid to high teens.

Headline financials

Total Revenue

$81.3M

Previous: $66.9M+21.5%
EPS (adj)

$0.01

Previous: -$0.11+109.4%
Adjusted EBITDA

$14.1M

No prior period
Gross Margin

83.3%

No prior period
Capital Expenditures

-$932K

Previous: -$498K-87.1%
Free Cash Flow

$268K

Previous: -$11.4M+102.4%
Net Income

$1.2M

Previous: -$10.9M+111.0%
Operating Income

$2.79M

Previous: -$9.64M+128.9%
Gross Profit

$67.7M

Previous: $55.1M+22.9%
Cash & Equivalents

$68.7M

Previous: $72.5M-5.3%
Total Assets

$176M

Previous: $169M+4.6%

Revenue & EPS history

Mimedx · Revenue · Quarterly

$81.3M

Q2 2023+21.5%vs Q2 2022
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Forward guidance

MiMedx expects full year 2023 net sales growth in the mid-to-upper teens as a percentage. Adjusted EBITDA margin in the second half of 2023 is expected to exceed 20%.

Tailwinds

  • Continued demand for the Company’s Wound & Surgical product offering across its sites of service.
  • Ongoing uptake of new products launched in the last twelve months.
  • Financial benefits associated with the Company’s recently announced strategic realignment.
  • Expects full year 2023 net sales growth in the mid-to-upper teens as a percentage.
  • Adjusted EBITDA margin in the second half of 2023 is expected to exceed 20%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+1.7%

Avg return

Earnings day

+2.9%

Avg return

5 days after

+7.2%

Avg return

30 days after

53%

34 / 64 earnings

Positive

+37.9%

Q1 2023

Best reaction

-23.3%

Q3 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-9.1%+6.2%+8.2%
Q4 2025-0.9%-8.8%-28.8%
Q3 2025+2.6%+7.0%-4.3%
Q1 2025-8.1%-3.9%-6.5%
Q4 2024+1.6%+1.1%-5.9%
Q3 2024+17.9%+22.7%+59.2%
Q2 2024-12.0%-17.7%-9.9%
Q1 2024+16.8%+17.7%+13.7%
Q4 2023-2.9%-1.7%-8.3%
Q3 2023+6.7%+10.9%+26.5%
Q2 2023-4.6%-4.2%-8.1%
Q1 2023+37.9%+49.1%+50.4%
Q4 2022-11.4%-6.4%-29.0%
Q3 2022-3.6%+1.3%+12.6%
Q2 2022+8.2%+15.5%+2.3%
Q1 2022+11.1%-8.9%-4.8%
Q4 2021+1.4%-1.6%-4.0%
Q3 2021+18.8%+22.6%+2.5%
Q2 2021-2.5%+1.4%+23.4%
Q1 2021-2.9%-5.0%+2.0%
Q4 2020-15.3%-13.4%+13.8%
Q3 2020+3.4%-8.2%-5.6%
Q2 2020+2.3%+4.2%+14.4%
Q2 2018+8.2%+3.2%+18.2%
Q1 2020+8.2%+3.2%+18.2%
Q4 2018+8.2%+3.2%+18.2%
Q4 2019+8.2%+3.2%+18.2%
Q2 2019+8.2%+3.2%+18.2%
Q1 2018+8.2%+3.2%+18.2%
Q1 2019+8.2%+3.2%+18.2%
Q3 2019+8.2%+3.2%+18.2%
Q4 2017-21.6%-22.1%-14.0%
Q3 2018-1.3%-8.6%-7.0%
Q3 2017+4.1%+8.7%-4.9%
Q2 2017+0.7%+2.1%+5.9%
Q1 2017+8.2%+19.1%+17.5%
Q4 2016-3.9%+3.4%+9.8%
Q3 2016+4.9%+8.0%+19.1%
Q2 2016-0.9%-1.7%-5.6%
Q1 2016-1.4%
Q4 2015-0.4%
Q3 2015-23.3%
Q2 2015-13.5%
Q1 2015+0.9%
Q4 2014+8.7%
Q3 2014+13.2%
Q2 2014+5.5%
Q1 2014-3.8%
Q4 2013+2.2%
Q3 2013-3.5%
Q2 2013+0.8%
Q1 2013-2.2%
Q4 2012+8.5%
Q3 2012+13.5%
Q2 2012-4.8%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011-4.2%
Q2 2011-2.5%
Q1 2011-3.7%
Q4 2010+5.8%
Q3 2010+0.0%
Q2 2010-4.8%
Q1 2010+4.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro